SLC6A14 and cancer: SLC6A14 has potential as a therapeutic target for both drug delivery and treatment of cancer [6], but also in other pathophysiological conditions associated with increased expression of this transporter such as the inflammatory bowel diseases ulcerative colitis and Crohn’s disease [6,34,35].